VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer

VOLITIONRX LTD

Received $13.0 million in milestone payments from Heska Corporation.
Milestone triggered by successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ point-of-care platform.
Payment stems from March 2022 License and Supply Agreement between Belgian Volition SRL and Heska.
Test is marketed as the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor.'

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.